Crinetics Pharmaceuticals (CRNX) Income from Continuing Operations (2017 - 2026)
Crinetics Pharmaceuticals (CRNX) recorded quarterly Income from Continuing Operations of 127714000.0 in Q1 2026, down 4.14% quarter-over-quarter from 122635000.0 in Q4 2025, and down 32.25% on a YoY basis from 188504442.96 in Q1 2025.
Crinetics Pharmaceuticals (CRNX) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Crinetics Pharmaceuticals' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 127714000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 32.25% year-over-year to 127714000.0; the TTM figure through Mar 2026 stood at 496097000.0 (down 51.23% YoY), while the FY2025 annual figure was 465317000.0, down 56.18% from the prior year.
- Income from Continuing Operations was 127714000.0 for Q1 2026 at Crinetics Pharmaceuticals, down from 122635000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 33634000.0 in Q1 2022 to a low of 130091000.0 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 74298764.71 across 5 years, with a median of 66209000.0 in 2024.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations slipped 20.23% in 2023, then plunged 69.33% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 45652000.0 in 2022, then dropped by 22.53% to 55936000.0 in 2023, then plunged by 44.08% to 80595000.0 in 2024, then sank by 52.16% to 122635000.0 in 2025, then fell by 4.14% to 127714000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 127714000.0 (Q1 2026), 122635000.0 (Q4 2025), and 130091000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Crinetics Pharmaceuticals | 3.58 Bn | 3.58 Bn | 10.53 Mn | -127.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -127.71 Mn |
| Dec 31, 2025 | -122.64 Mn |
| Sep 30, 2025 | -130.09 Mn |
| Jun 30, 2025 | -115.66 Mn |
| Mar 31, 2025 | -96.57 Mn |
| Dec 31, 2024 | -80.60 Mn |
| Sep 30, 2024 | -76.83 Mn |
| Jun 30, 2024 | -74.04 Mn |
| Mar 31, 2024 | -66.21 Mn |
| Dec 31, 2023 | -55.94 Mn |
| Sep 30, 2023 | -56.41 Mn |
| Jun 30, 2023 | -50.89 Mn |
| Mar 31, 2023 | -45.94 Mn |
| Dec 31, 2022 | -45.65 Mn |
| Sep 30, 2022 | -41.95 Mn |
| Jun 30, 2022 | -42.33 Mn |
| Mar 31, 2022 | -33.63 Mn |
| Dec 31, 2021 | -30.81 Mn |
| Sep 30, 2021 | -27.78 Mn |
| Jun 30, 2021 | -26.07 Mn |